Related references
Note: Only part of the references are listed.Discovery of Reversible Inhibitors of KDM1A Efficacious in Acute Myeloid Leukemia Models
Alessia Romussi et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Design, synthesis and biological evaluation of tetrahydroquinoline-based reversible LSD1 inhibitors
Xinran Wang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy
Tingting Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Two-hit wonders: The expanding universe of multitargeting epigenetic agents
Angel R. de Lera et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2020)
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
Terence C. S. Ho et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Epigenetic Therapies for Cancer
Susan E. Bates
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective
Xing-Jie Dai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Histone lysine specific demethylase 1 inhibitors
Samir Mehndiratta et al.
RSC MEDICINAL CHEMISTRY (2020)
Elucidating the mechanism of action of domatinostat (4SC-202) in cutaneous T cell lymphoma cells
Marion Wobser et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Expanding the Role of the Histone Lysine-Specific Demethylase LSD1 in Cancer
Barbara Majello et al.
CANCERS (2019)
Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines
Darcy Welch et al.
PLOS ONE (2019)
Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG
Jamie N. Anastas et al.
CANCER CELL (2019)
Genetics meets DNA methylation in rare diseases
Guillaume Velasco et al.
CLINICAL GENETICS (2019)
Next-generation of selective histone deacetylase inhibitors
Feifei Yang et al.
RSC ADVANCES (2019)
Novel polyamine-based Histone deacetylases-Lysine demethylase 1 dual binding inhibitors
Andrea Milelli et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells
Chunyu Cao et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors
Jay H. Kalin et al.
NATURE COMMUNICATIONS (2018)
Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy
Yingchao Duan et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
LSD1 coordinates with the SIN3A/HDAC complex and maintains sensitivity to chemotherapy in breast cancer
Yang Yang et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2018)
LSD1 Substrate Binding and Gene Expression Are Affected by HDAC1-Mediated Deacetylation
Dhanusha A. Nalawansha et al.
ACS CHEMICAL BIOLOGY (2017)
Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression
C. Cao et al.
ONCOGENE (2017)
Structural insight into inhibitors of flavin adenine dinucleotide-dependent lysine demethylases
Hideaki Niwa et al.
EPIGENETICS (2017)
Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment
Ying-Chao Duan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Design, synthesis and biological evaluation of [1,2,4]triazolo[1,5-a]pyrimidines as potent lysine specific demethylase 1 (LSD1/KDM1A) inhibitors
Shuai Wang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Discovery of resveratrol derivatives as novel LSD1 inhibitors: Design, synthesis and their biological evaluation
Ying-Chao Duan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Advances toward LSD1 inhibitors for cancer therapy
Xiaoli Fu et al.
FUTURE MEDICINAL CHEMISTRY (2017)
Thieno[3,2-b]pyrrole-5-carboxamides as New Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1. Part 2: Structure-Based Drug Design and Structure-Activity Relationship
Paola Vianello et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat
Chiara Zagni et al.
MEDICINAL RESEARCH REVIEWS (2017)
Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4-and MYC-dependent manner
Vivek Kumar Mishra et al.
NUCLEIC ACIDS RESEARCH (2017)
LSD1 demethylates HIF1α to inhibit hydroxylation and ubiquitin-mediated degradation in tumor angiogenesis
J-Y Lee et al.
ONCOGENE (2017)
Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells
Tinka Haydn et al.
CELL DEATH & DISEASE (2017)
4SC-202 as a Potential Treatment for the Pediatric Brain Tumor Medulloblastoma
Shanta M. Messerli et al.
BRAIN SCIENCES (2017)
4SC-202 activates ASK1-dependent mitochondrial apoptosis pathway to inhibit hepatocellular carcinoma cells
Meili Fu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2016)
Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment
Yi C. Zheng et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2016)
LSD1 inhibitors: a patent review (2010-2015)
Giulia Stazi et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2016)
Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs
Kathy A. Gelato et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2016)
Recent Progress in Histone Demethylase Inhibitors
Tom E. McAllister et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines
Maria Pinkerneil et al.
TARGETED ONCOLOGY (2016)
Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells
Huang Zhijun et al.
TUMOR BIOLOGY (2016)
LSD1: biologic roles and therapeutic targeting
Alba Maiques-Diaz et al.
EPIGENOMICS (2016)
Design, Synthesis, and Structure-Activity Relationship of Novel LSD1 Inhibitors Based on Pyrimidine-Thiourea Hybrids As Potent, Orally Active Antitumor Agents
Li-Ying Ma et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
A Systematic Review of Histone Lysine-Specific Demethylase 1 and Its Inhibitors
Yi-Chao Zheng et al.
MEDICINAL RESEARCH REVIEWS (2015)
Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma
Melissa M. Singh et al.
NEURO-ONCOLOGY (2015)
Reversible Inhibitors of LSD1 as Therapeutic Agents in Acute Myeloid Leukemia: Clinical Significance and Progress to Date
Daniel P. Mould et al.
MEDICINAL RESEARCH REVIEWS (2015)
LSD1 Regulates Pluripotency of Embryonic Stem/Carcinoma Cells through Histone Deacetylase 1-Mediated Deacetylation of Histone H4 at Lysine 16
Feng Yin et al.
MOLECULAR AND CELLULAR BIOLOGY (2014)
Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells
W. Fiskus et al.
LEUKEMIA (2014)
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Katrina J. Falkenberg et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
CD86 expression as a surrogate cellular biomarker for pharmacological inhibition of the histone demethylase lysine-specific demethylase 1
James T. Lynch et al.
ANALYTICAL BIOCHEMISTRY (2013)
Triazole-Dithiocarbamate Based Selective Lysine Specific Demethylase 1 (LSD1) Inactivators Inhibit Gastric Cancer Cell Growth, Invasion, and Migration
Yi-Chao Zheng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
High-Throughput Virtual Screening Identifies Novel N′-(1-Phenylethylidene)-benzohydrazides as Potent, Specific, and Reversible LSD1 Inhibitors
Venkataswamy Sorna et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Histone lysine demethylases as targets for anticancer therapy
Jonas W. Hojfeldt et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
The Deubiquitinase USP28 Stabilizes LSD1 and Confers Stem-Cell-like Traits to Breast Cancer Cells
Yadi Wu et al.
CELL REPORTS (2013)
Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells
Yi Huang et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Demethylation of RB Regulator MYPT1 by Histone Demethylase LSD1 Promotes Cell Cycle Progression in Cancer Cells
Hyun-Soo Cho et al.
CANCER RESEARCH (2011)
Histone Deacetylase Inhibitors Stimulate Histone H3 Lysine 4 Methylation in Part Via Transcriptional Repression of Histone H3 Lysine 4 Demethylases
Po-Hsien Huang et al.
MOLECULAR PHARMACOLOGY (2011)
Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors
Melissa M. Singh et al.
NEURO-ONCOLOGY (2011)
Inside HDAC with HDAC inhibitors
Philippe Bertrand
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2010)
Lysine Methylation Regulates E2F1-Induced Cell Death
Haroula Kontaki et al.
MOLECULAR CELL (2010)
HDAC family: What are the cancer relevant targets?
Olaf Witt et al.
CANCER LETTERS (2009)
LSD1 Is a Subunit of the NuRD Complex and Targets the Metastasis Programs in Breast Cancer
Yan Wang et al.
CELL (2009)
The many roles of histone deacetylases in development and physiology: implications for disease and therapy
Michael Haberland et al.
NATURE REVIEWS GENETICS (2009)
p53 is regulated by the lysine demethylase LSD1
Jing Huang et al.
NATURE (2007)
LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription
E Metzger et al.
NATURE (2005)
An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation
MG Lee et al.
NATURE (2005)
Histone demethylation mediated by the nuclear arnine oxidase homolog LSD1
YJ Shi et al.
CELL (2004)
Share Paper
